# Phase 01 — Windows Local Engineering Foundation Verification (2026-11-02)

**Decision status:** **OWNER ACCEPTED — LIMITED WINDOWS ENGINEERING FOUNDATION ONLY**, as explicitly approved by the owner in ChatGPT on 2026-11-02. **GitHub PR #20 remains DRAFT and UNMERGED**; independent security acceptance, production, clinical use and next-task authorization remain blocked.  
**Scope:** P01-T01 through P01-T05-D engineering/security foundation only, not the complete Phase 01 functional scope.  
**Release classification accepted by owner:** INTERNAL_FOUNDATION. **Not** CUSTOMER_PILOT or PRODUCTION_RELEASE. No live patient information, customer deployment, phase closure, next-task approval, or clinical use is authorized.  
**Evidence provenance:** Sanitized Windows PowerShell outputs provided by the repository owner in the ChatGPT support session on 2026-11-02. These commands were run on the owner's machine, **not independently executed** by the reviewer/assistant. Results are recorded as *user-reported local observations*; pre-upgrade states and omitted checks are not inferred.

## Windows evidence register

| Gate | User-provided evidence | Assessment |
|---|---|---|
| Repository integrity | git ls-files --deleted returned no paths after restoring tracked files | PASS for missing tracked files at time checked; not an independent repository audit |
| Docker PostgreSQL | Compose --force-recreate --wait postgres returned container Healthy | PASS: running local development container |
| Database roles | pg_roles query returned aronexa_app_runtime and aronexa_auth_runtime; both LOGIN=true, SUPERUSER=false, BYPASSRLS=false | PASS: role flags; not a complete direct privilege audit |
| Flyway schema | Query of flyway_schema_history showed V1, V2, V3, V4, V5 and V6, each success=true | PASS: six applied migrations; prior pre-upgrade history not captured |
| Backend compilation | mvn -f .\\backend\\pom.xml clean test-compile ended BUILD SUCCESS, compiling 17 main and 8 test source files | PASS |
| Backend test execution | Maven Surefire text summaries show 53 tests, 0 failures, 0 errors, 0 skipped in eight suites | PASS: test profile / Testcontainers test evidence |
| Spring Boot local startup | Log: Started AronexaApplication in 2.46 seconds (process running for 2.742) | PASS: application started; active profile/version not independently captured |
| Frontend build | npm run build: TypeScript and Vite 7.3.7, 29 modules transformed, build succeeded | PASS |
| Frontend security audit | npm audit reported found 0 vulnerabilities after Vite 7.3.7 upgrade | PASS for that recorded npm audit snapshot, not all security risks |
| Authenticated-session denial | GET http://127.0.0.1:8080/api/v1/auth/me returned HTTP 401 and no-cache / nosniff / frame-deny headers | PASS: unauthenticated smoke test |
| Invalid-login denial | POST /api/v1/auth/login with synthetic unknown credentials returned HTTP Status: 401 | PASS: invalid-login smoke test |
| Fix for Windows CRLF / Vite vulnerabilities | GitHub PR #19 merged to main; .gitattributes LF rule and Vite dependency/lockfile update | PASS: merged change, CI PR Quality Gates succeeded |
| Local Git whitespace check | git diff --check produced no errors; initdb script was i/lf w/lf and had no non-line-ending diff | PASS at recorded checkout |
| Post-upgrade clean install reproducibility | Earlier npm clean install succeeded; later commands using wrong working directory failed; no final post-upgrade npm ci output was supplied | NOT VERIFIED specifically for fresh local installation after upgrade; PR CI success is separate |
| Exact Windows kit, Windows offline installer, valid UI login | Acceptance kit not found; no seeded login/browser login flow; no offline installer tested | NOT RUN / NOT IMPLEMENTED |
| Existing-volume upgrade assurance | V1–V6 are present in current local DB, but no saved *pre-migration* version history, verified backup, or independently recorded V5→V6 transition | PARTIAL; not a verified recovery/upgrade rehearsal |

### Backend test suite evidence

| Suite | Tests | Failures | Errors | Skipped |
|---|---:|---:|---:|---:|
| ArchitectureTests | 1 | 0 | 0 | 0 |
| AronexaApplicationTests | 4 | 0 | 0 | 0 |
| AuthenticationIntegrationTests | 12 | 0 | 0 | 0 |
| AuthRoleBoundaryTests | 4 | 0 | 0 | 0 |
| OrganizationAccessIntegrationTests | 7 | 0 | 0 | 0 |
| PostgresTenantRlsTests | 8 | 0 | 0 | 0 |
| TenantAuthorizationTests | 8 | 0 | 0 | 0 |
| OrganizationPersistenceTests | 9 | 0 | 0 | 0 |
| **Total** | **53** | **0** | **0** | **0** |

### Traceable repository evidence

- [P01-T05-D security work and limits](P01_T05D_BUILD_LOG.md): separate auth DB role, PostgreSQL tests and known risks.
- [Phase 01 security closure baseline](P01_SECURITY_CLOSURE_ACCEPTANCE.md): release limitations and controlled local runbook.
- [PR #19 — Vite 7.3.7 and LF script enforcement](https://github.com/ARG-Digital-Solutions/aronexa-healthcare-platform/pull/19): merged on 2026-11-02; PR Quality Gates succeeded.
- [Phase 01 task cards](PHASE_01_TASK_CARDS.md): P01-T06 through P01-T10 are not established as complete by these checks.
- [Release gate](../releases/RELEASE_GATE.md): explicit owner approval and separate clinical/production acceptance.

## Residual security risk review (no waiver implied)

| ID | Priority for real-data/customer use | Finding and evidence boundary | Required resolution or gate |
|---|---|---|---|
| SEC-01 | HIGH / PRODUCTION BLOCKER | The dedicated auth role still has global table-level SQL access to accounts/sessions where grants permit it. Separate DB principals reduce exposure but do not establish full auth-tenant isolation; SQL injection risk remains. | Independently review and restrict identity/session data access (e.g., narrowly scoped function/interface architecture), negative-test cross-tenant auth access, approve any privilege model change |
| SEC-02 | HIGH / CLINICAL BLOCKER | Patient, doctor, encounter, prescription, and doctor-to-branch clinical object policies are not implemented or tested; organization RLS tests do not substitute for clinical authorization. | Implement relevant models and API object/branch/role checks, IDOR tests, negative concurrency and RLS checks before clinical data |
| SEC-03 | HIGH / CUSTOMER BLOCKER | MFA, verified recovery, safe user provisioning, privileged support/emergency access, robust abuse throttling and session-theft hardening remain incomplete. | Threat-model and implement controls with authenticated API and adversarial tests; explicit security review |
| SEC-04 | HIGH / RELEASE BLOCKER | Backup restoration, rollback/recovery, existing-volume upgrade rehearsal and customer migration integrity have not been demonstrated. | Back up a synthetic nonempty DB, verify restore, test forward-only migration and document recovery. Never use Flyway clean or remove named volumes to pass tests |
| SEC-05 | HIGH / RELEASE BLOCKER | Legal/privacy applicability, data retention, clinician authorization, audit and real clinical workflow review are not completed. | Privacy/security and clinician signoff before handling actual patient data or customer release |
| SEC-06 | MEDIUM / ACCEPTANCE GAP | The two local 401 checks validate only rejection paths; no positive authenticated login or browser E2E was exercised. No valid dev account was seeded. | Approved synthetic-only account provisioning, valid-login/logout, permissions, browser and relevant role-negative verification |
| SEC-07 | MEDIUM / VERIFICATION GAP | No final local post-upgrade clean npm ci transcript, tool-version inventory, frontend screenshot, or complete Windows installer acceptance evidence supplied. | Capture reproducible build and environment metadata; distinguish local web developer startup from Windows offline installation |
| SEC-08 | ONGOING | The zero-finding npm audit is a point-in-time dependency check, not a penetration test, full-history secret scan or supply-chain certification. | Maintain patched dependencies and reviewed CI scans; independent security review before production |

**Residual-risk disposition:** No security blocker is deemed fixed solely by passing the 53 Java tests, 6 migrations, two 401 smoke tests, or npm audit. Security risks above remain open and should be tracked as review items for future **separately approved** work. No patient data or production operations are authorized.

## V3 mandatory 16-field foundation review report

| # | Required field | Recorded decision/evidence |
|---|---|---|
| 1 | Phase and version | Phase 01 P01-T01–T05-D engineering foundation; local verification date 2026-11-02; merged PR #19 |
| 2 | Repository audit and reuse | ARG-Digital-Solutions/aronexa-healthcare-platform; previously missing tracked local files restored; no CareNexus reuse claimed or audited in this review |
| 3 | Features implemented | Java/React scaffolding, tenant/organization model, authentication foundation, restricted DB principals, organization scope/RLS; not clinical workflows |
| 4 | Database/API changes | Flyway V1–V6 applied; auth/me and auth/login rejection tested. No clinical endpoints certified |
| 5 | UI/UX and stylus | Vite/TypeScript foundation build only; no reception, OPD prescription or stylus UI acceptance |
| 6 | Security/clinical impact | SEC-01 to SEC-08 open; organization isolation tests pass but auth/clinical boundary gaps remain |
| 7 | Test commands/results | Maven clean test-compile passed; 53/53 Surefire tests; PostgreSQL role/history queries; npm build; npm audit 0; two HTTP 401 checks |
| 8 | Regression evidence | Eight local backend test suites passed; prior CI evidence for PR #17/#19 separate; no full patient workflow regression |
| 9 | Compliance | No compliance certification; healthcare privacy, applicable regulations and clinician safety review pending |
| 10 | Supported deployment modes | Local Windows developer setup only observed; SaaS, Windows offline standalone, dedicated, macOS and Android not acceptance-tested |
| 11 | Release artifacts | GitHub merged source PR #19 and user-supplied sanitized console evidence; no customer executable or installer approved |
| 12 | Remaining defects/risks | See SEC-01–SEC-08 and unimplemented P01-T06–T10 functional scope |
| 13 | Backup/recovery | Not tested; existing development volume preserved, no proven recovery rehearsal |
| 14 | Customer acceptance | NOT RUN; no patient data, pilot, clinical UAT or customer signoff |
| 15 | Release classification | Owner accepted INTERNAL_FOUNDATION only; not CUSTOMER_PILOT / PRODUCTION_RELEASE |
| 16 | Review recommendation | Limited Windows engineering-foundation verification OWNER ACCEPTED; full Phase 01 and deployment NOT READY; independent security review outstanding |

## Formal owner acceptance — LIMITED scope (2026-11-02)

**Owner's explicit decision (received in ChatGPT conversation, reproduced verbatim):**

> I formally approve AroNexa P01-T01 through P01-T05-D Windows engineering foundation as INTERNAL_FOUNDATION only, acknowledge all documented open risks, and do not authorize production, clinical use, merge, or the next development task.

**Recorded disposition:** **OWNER ACCEPTED** for the reported Windows local **engineering-foundation verification only**, with SEC-01–SEC-08 preserved as open risks. This is acceptance of the recorded scope and evidence, **not a waiver, remediation or independent validation** of residual security issues.

- Acceptance source: direct user instruction in ChatGPT on 2026-11-02; recorded on documentation review branch and PR #20, **not** an authenticated GitHub review or main-branch approval.
- Owner acceptance status: **APPROVED (LIMITED INTERNAL_FOUNDATION)**.
- Independent security reviewer acceptance of residual auth/data isolation risk: **PENDING**.
- Full Phase 01: **NOT COMPLETE**. Remaining P01-T06–P01-T10 and clinical-object portion of T05 not authorized/completed by this approval.
- Production, customer deployment, clinical use and live patient data: **NOT AUTHORIZED**.
- Documentation PR #20: **REMAIN DRAFT, DO NOT MERGE**, as explicitly instructed by the owner. Recording acceptance in the review branch does not amend `main`.
- Next development task: **NOT AUTHORIZED**; separate explicit scoped task approval is required.
- Backup/restore, environment inventory, clean-install proof and other unverified gates stay NOT RUN / PARTIAL; these do not silently become PASS.

**Document control:** Acceptance is recorded in this draft PR for later review. No code, migrations, deployments, merges, or next-phase tasks were executed as part of this acceptance record.
